Treatment effect of idebenone on inspiratory function in patients with Duchenne muscular dystrophy

Assessment of dynamic inspiratory function may provide valuable information about the degree and progression of pulmonary involvement in patients with Duchenne muscular dystrophy (DMD). The aims of this study were to characterize inspiratory function and to assess the efficacy of idebenone on this pulmonary function outcome in a large and well‐characterized cohort of 10–18 year‐old DMD patients not taking glucocorticoid steroids (GCs) enrolled in the phase 3 randomized controlled DELOS trial. We evaluated the effect of idebenone on the highest flow generated during an inspiratory FVC maneuver (maximum inspiratory flow; V'I,max(FVC)) and the ratio between the largest inspiratory flow during tidal breathing (tidal inspiratory flow; V'I,max(t)) and the V'I,max(FVC). The fraction of the maximum flow that is not used during tidal breathing has been termed inspiratory flow reserve (IFR). DMD patients in both treatment groups of DELOS (idebenone, n = 31; placebo: n = 33) had comparable and abnormally low V'I,max(FVC) at baseline. During the study period, V'I,max(FVC) further declined by −0.29 L/sec in patients on placebo (95%CI: −0.51, −0.08; P = 0.008 at week 52), whereas it remained stable in patients on idebenone (change from baseline to week 52: 0.01 L/sec; 95%CI: −0.22, 0.24; P = 0.950). The between‐group difference favoring idebenone was 0.27 L/sec (P = 0.043) at week 26 and 0.30 L/sec (P = 0.061) at week 52. In addition, during the study period, IFR improved by 2.8% in patients receiving idebenone and worsened by −3.0% among patients on placebo (between‐group difference 5.8% at week 52; P = 0.040). Although the clinical interpretation of these data is currently limited due to the scarcity of routine clinical practice experience with dynamic inspiratory function outcomes in DMD, these findings from a randomized controlled study nevertheless suggest that idebenone preserved inspiratory muscle function as assessed by V'I,max(FVC) and IFR in patients with DMD. Pediatr Pulmonol. 2017;52:508–515. © 2016 The Authors. Pediatric Pulmonology Published by Wiley Periodicals, Inc.

[1]  T. Voit,et al.  Home-Based Monitoring of Pulmonary Function in Patients with Duchenne Muscular Dystroph , 2018, Journal of neuromuscular diseases.

[2]  M. Leinonen,et al.  Efficacy of Idebenone to Preserve Respiratory Function above Clinically Meaningful Thresholds for Forced Vital Capacity (FVC) in Patients with Duchenne Muscular Dystrophy , 2017, Journal of neuromuscular diseases.

[3]  J. J. Padilla,et al.  Idebenone reduces respiratory complications in patients with Duchenne muscular dystrophy , 2016, Neuromuscular Disorders.

[4]  R. Finkel,et al.  Efficacy of idebenone on respiratory function in patients with Duchenne muscular dystrophy not using glucocorticoids (DELOS): a double-blind randomised placebo-controlled phase 3 trial , 2015, The Lancet.

[5]  N. Goemans,et al.  Current Treatment and Management of Dystrophinopathies , 2014, Current Treatment Options in Neurology.

[6]  S. Bourke.  Respiratory involvement in neuromuscular disease. , 2014, Clinical medicine.

[7]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[8]  R. Abresch,et al.  P.11.12 Pulmonary function characteristics of boys with Duchenne muscular dystrophy: Data from the CINRG longitudinal study project , 2013, Neuromuscular Disorders.

[9]  R. Abresch,et al.  P.11.11 Pulmonary function characteristics of boys with Duchenne Muscular Dystrophy by age groups, ambulatory status and steroid use , 2013, Neuromuscular Disorders.

[10]  T. Grimm,et al.  Survival in Duchenne muscular dystrophy , 2012, Acta myologica : myopathies and cardiomyopathies : official journal of the Mediterranean Society of Myology.

[11]  G. Piluso,et al.  Improvement of survival in Duchenne Muscular Dystrophy: retrospective analysis of 835 patients , 2012, Acta myologica : myopathies and cardiomyopathies : official journal of the Mediterranean Society of Myology.

[12]  J. Bach,et al.  The respiratory management of patients with duchenne muscular dystrophy: A DMD care considerations working group specialty article , 2010, Pediatric pulmonology.

[13]  J. Goldstein,et al.  Perspectives on: SGP Symposium on Muscle in Health and Disease: Mechanisms of muscle weakness in muscular dystrophy , 2010 .

[14]  Craig McDonald,et al.  Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care , 2010, The Lancet Neurology.

[15]  R. Finkel,et al.  Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management , 2010, The Lancet Neurology.

[16]  J. Carlin,et al.  Height prediction from ulna length. , 2004, Developmental medicine and child neurology.

[17]  J. Carlin,et al.  Prediction of childhood pulmonary function using ulna length. , 2003, American Journal of Respiratory and Critical Care Medicine.

[18]  R. Doménech-Clar,et al.  Maximal static respiratory pressures in children and adolescents , 2003, Pediatric pulmonology.

[19]  Colin Chandler,et al.  Survival in Duchenne muscular dystrophy: improvements in life expectancy since 1967 and the impact of home nocturnal ventilation , 2002, Neuromuscular Disorders.

[20]  A. Simonds.  Respiratory Complications of the Muscular Dystrophies , 2002, Seminars in respiratory and critical care medicine.

[21]  Gary C. Sieck,et al.  ATS/ERS Statement on respiratory muscle testing. , 2002, American journal of respiratory and critical care medicine.

[22]  K. Carlsen,et al.  Lung function in children with Duchenne's muscular dystrophy. , 2001, Respiratory medicine.

[23]  N. Pride,et al.  Inspiratory flow reserve in boys with Duchenne muscular dystrophy , 2001, Pediatric pulmonology.

[24]  J L Hankinson,et al.  Spirometric reference values from a sample of the general U.S. population. , 1999, American journal of respiratory and critical care medicine.

[25]  C. Roussos,et al.  Inspiratory maneuver effects on peak expiratory flow. Role of lung elastic recoil and expiratory pressure. , 1997, American journal of respiratory and critical care medicine.

[26]  N. Pride,et al.  Diaphragm thickness and inspiratory strength in patients with Duchenne muscular dystrophy. , 1997, Thorax.

[27]  O. Pedersen.  The Peak Flow Working Group: physiological determinants of peak expiratory flow. , 1997, The European respiratory journal. Supplement.

[28]  J. Bach,et al.  Clinical implications of maximal respiratory pressure determinations for individuals with Duchenne muscular dystrophy. , 1997, Archives of physical medicine and rehabilitation.

[29]  A. Vianello,et al.  Cardiac and respiratory involvement in advanced stage Duchenne muscular dystrophy , 1996, Neuromuscular Disorders.

[30]  R. Abresch,et al.  Profiles of neuromuscular diseases. Becker's muscular dystrophy. , 1995, American journal of physical medicine & rehabilitation.

[31]  R. Abresch,et al.  Profiles of neuromuscular diseases. Duchenne muscular dystrophy. , 1995, American journal of physical medicine & rehabilitation.

[32]  J. Stocks,et al.  Compilation of reference values for lung function measurements in children. , 1989, The European respiratory journal. Supplement.

[33]  M. Cosio,et al.  Flow-volume loop changes reflecting respiratory muscle weakness in chronic neuromuscular disorders. , 1987, The American journal of medicine.

[34]  P. Calverley,et al.  Practical problems in the respiratory care of patients with muscular dystrophy. , 1987, The New England journal of medicine.

[35]  N. Pride,et al.  The respiratory system in neuromuscular disorders , 1985 .

[36]  J. Newsom-Davis,et al.  The respiratory system in muscular dystrophy. , 1980, British medical bulletin.

[37]  N. Pride,et al.  Pulmonary mechanics in patients with respiratory muscle weakness. , 2015, The American review of respiratory disease.